Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation.

Zhang YM, Dai BL, Zheng L, Zhan YZ, Zhang J, Smith WW, Wang XL, Chen YN, He LC.

Cell Death Dis. 2012 Oct 11;3:e406. doi: 10.1038/cddis.2012.145.

2.

Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.

3.

Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways.

Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, Chen G, Luo J, Shi X.

PLoS One. 2012;7(10):e47516. doi: 10.1371/journal.pone.0047516. Epub 2012 Oct 18.

4.

Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways.

Zhang L, Ji Q, Liu X, Chen X, Chen Z, Qiu Y, Sun J, Cai J, Zhu H, Li Q.

Cancer Sci. 2013 May;104(5):604-10. doi: 10.1111/cas.12120. Epub 2013 Mar 20.

6.
7.

VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.

Doi Y, Yashiro M, Yamada N, Amano R, Noda S, Hirakawa K.

Ann Surg Oncol. 2012 Aug;19(8):2733-43. doi: 10.1245/s10434-011-2181-6. Epub 2011 Dec 30.

PMID:
22207048
9.

Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.

Chen MC, Lee CF, Huang WH, Chou TC.

Biochem Pharmacol. 2013 May 1;85(9):1278-87. doi: 10.1016/j.bcp.2013.02.009. Epub 2013 Feb 14.

PMID:
23416116
10.

Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.

Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE.

Lab Invest. 2009 Jan;89(1):38-46. doi: 10.1038/labinvest.2008.106. Epub 2008 Nov 10.

11.

Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2.

Lai L, Liu J, Zhai D, Lin Q, He L, Dong Y, Zhang J, Lu B, Chen Y, Yi Z, Liu M.

Br J Pharmacol. 2012 Feb;165(4b):1084-96. doi: 10.1111/j.1476-5381.2011.01532.x.

12.

Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.

Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC.

Invest New Drugs. 2013 Feb;31(1):1-13. doi: 10.1007/s10637-012-9817-7. Epub 2012 Apr 27.

PMID:
22539090
13.

Brucine suppresses colon cancer cells growth via mediating KDR signalling pathway.

Luo W, Wang X, Zheng L, Zhan Y, Zhang D, Zhang J, Zhang Y.

J Cell Mol Med. 2013 Oct;17(10):1316-24. doi: 10.1111/jcmm.12108. Epub 2013 Aug 2.

14.

YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Xia Y, Song X, Li D, Ye T, Xu Y, Lin H, Meng N, Li G, Deng S, Zhang S, Liu L, Zhu Y, Zeng J, Lei Q, Pan Y, Wei Y, Zhao Y, Yu L.

Sci Rep. 2014 Aug 12;4:6031. doi: 10.1038/srep06031.

15.

KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth.

Nakamura K, Yamamoto A, Kamishohara M, Takahashi K, Taguchi E, Miura T, Kubo K, Shibuya M, Isoe T.

Mol Cancer Ther. 2004 Dec;3(12):1639-49.

16.

12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.

Xu HY, Pan YM, Chen ZW, Lin Y, Wang LH, Chen YH, Jie TT, Lu YY, Liu JC.

J Ethnopharmacol. 2013 Apr 19;146(3):724-33. doi: 10.1016/j.jep.2013.01.007. Epub 2013 Feb 19.

PMID:
23434607
17.

Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.

Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M.

Int J Cancer. 2010 Sep 1;127(5):1197-208. doi: 10.1002/ijc.25137.

18.

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.

Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS.

Mol Cancer Ther. 2007 Feb;6(2):471-83.

19.

Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.

Wang N, Wang ZY, Mo SL, Loo TY, Wang DM, Luo HB, Yang DP, Chen YL, Shen JG, Chen JP.

Breast Cancer Res Treat. 2012 Aug;134(3):943-55. doi: 10.1007/s10549-012-1977-9. Epub 2012 Feb 21.

20.

The antitumor effect of a novel angiogenesis inhibitor (an octahydronaphthalene derivative) targeting both VEGF receptor and NF-κB pathway.

Watari K, Nakamura M, Fukunaga Y, Furuno A, Shibata T, Kawahara A, Hosoi F, Kuwano T, Kuwano M, Ono M.

Int J Cancer. 2012 Jul 15;131(2):310-21. doi: 10.1002/ijc.26356. Epub 2011 Sep 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk